Jim Cramer's 'Mad Money' Recap: The Market's New Reality
at The Street - Wed Apr 23, 7:20PM CDT
Investors are focusing on the positive instead of the negative, Cramer says.
Encouraging Results from Pfizer's Xeljanz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 5:20PM CDT
Pfizer Inc. (PFE) announced encouraging top-line results from two pivotal phase III studies from the OPT Program on Xeljanz.
Fitch Places Allergan's Ratings on Negative Watch
Business Wire - Wed Apr 23, 2:32PM CDT
Fitch Ratings has placed the ratings for Allergan Inc. (Allergan), including the 'A+' Issuer Default Rating (IDR), on Rating Watch Negative. The rating action stems from Valeant Pharmaceuticals International Inc.'s (Valeant) unsolicited offer to acquire Allergan for approximately $45.6 billion. The rating action applies to $2.1 billion of outstanding Allergan debt. A complete list of ratings is provided at the end of this release.
Can Allergan Find an Alternative To Valeant?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 23, 1:30PM CDT
No one will accuse Valeant CEO Mike Pearson of lacking boldness. He has laid out a strategy for turning Valeant into one of the largest pharmaceutical/med-tech companies in the world and has proven more than willing to turn to bold...
Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results
Critical Alerts For Allergan, SunEdison, Valeant Pharmaceuticals, Shire PLC, and Paychex Released By InvestorsObserver
PR Newswire - Wed Apr 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AGN, SUNE, VRX, SHPG, and PAYX.
Stock Price Movements, Collaborations, Earnings Releases, Upcoming Earnings and Conference Call Schedules, and Legal Updates - Analyst Notes on Allergan, Aetna, Abbott, Amgen and Medtronic
PR Newswire - Wed Apr 23, 8:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Aetna Inc. (NYSE: AET), Abbott Laboratories (NYSE: ABT), Amgen Inc. (NASDAQ: AMGN) and Medtronic Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1477-100free.
Allergan, Inc.: Another Billion-Dollar Buyout Target
Max Macaluso and Michael Douglass, The Motley Fool - Motley Fool - Wed Apr 23, 8:15AM CDT
Earlier this week, investors following the pharmaceutical industry may have been surprised to hear that Pfizer was interested in acquiring AstraZeneca . However, the billion-dollar buyout news didn't stop there. Yesterday, shares of Allergan ,...
Why Valeant International Inc. Is Acquiring Botox and Juvederm Maker Allergan
Beth Nichols, The Motley Fool - Motley Fool - Wed Apr 23, 7:50AM CDT
Valeant Pharmaceuticals announced yesterday that it plans to acquire Allergan with the help of investor Bill Ackerman. Should the plan succeed, the acquisition would create a dermatology and ophthalmology giant and bring a number of the leading...
Allergan Inc. (AGN) in Focus: Stock Rallies 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:44AM CDT
Allergan Inc. was a big mover last session, as the company saw its shares surge over 15.0% on the day.
How Will Allergan (AGN) Stock Be Affected By Poison Pill Stance Against Valeant (VRX), Ackman?
at The Street - Wed Apr 23, 7:22AM CDT
Shares of Allergan (AGN) are slightly higher in pre-market trade after the health care company adopted a poison pill defense against the unsolicited $46 billion bid takeover from Valeant Pharmaceuticals (VRX) and activist investor Bill Ackman.
Downgrade Alert for Allergan (AGN)
Comtex SmarTrend(R) - Wed Apr 23, 6:57AM CDT
Allergan (AMEX:AGN) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $163.65 on volume of 32.4 million shares, above average daily volume of 3.4 million. In the past 52 weeks, shares of Allergan have traded between a low of $81.33 and a high of $165.45 and closed yesterday at $163.65, which is 101% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.7% while the 50-day MA has advanced 1.1%.
Wednesday's Artery-Clogging Fast-Food Earnings Reports, and Potential Botox Merger
Jack Kramer and Nick Martell, The Motley Fool - Motley Fool - Wed Apr 23, 5:00AM CDT
Get ready to pack an artery with some corporate earnings from America's publicly traded fast-food all-stars. The Dow rose 65 points Tuesday as investors continue to eat up stocks like they're mid McNugget-binge. 1. McDonald's first-quarter...
MarketResearchReports.Com: Migraine - United States Drug Forecast and Market Analysis to 2023, New Report Launched
M2 - Wed Apr 23, 3:57AM CDT
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
ALLERGAN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Allergan, Inc.
PR Newswire - Tue Apr 22, 9:24PM CDT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF"
Valeant, Ackman make $45.6B Allergan bid
AP - Tue Apr 22, 7:43PM CDT
NEW YORK (AP) — Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.
Allergan Adopts One-Year Stockholder Rights Plan
Business Wire - Tue Apr 22, 7:25PM CDT
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
Jim Cramer's 'Mad Money' Recap: Opportunities Are Still Out There
at The Street - Tue Apr 22, 7:13PM CDT
There have been many sectors that have not been participating in the market's rally -- until today, Cramer says.
Drugmakers Prod European Stocks To Post-Easter Rally
at Investor's Business Daily - Tue Apr 22, 5:36PM CDT
European exchanges were high scorers on the world map Tuesday, as investors returned with vigor from the four-day holiday. Germany's Frankfurt Exchange led the pack, with the DAX index vaulting 2% higher. In Italy, Milano's FTSE MIB punched up 1.5%....
NYSE stocks posting largest volume increases
AP - Tue Apr 22, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading: